Quotient Clinical and Capsugel have partnered to accelerate early development and clinical evaluation of lipid-based formulations.
The collaboration will focus on addressing the drug delivery challenges of poorly soluble molecules with limited oral bioavailability by integrating Quotient's RapidFACTTM clinical manufacture and testing service with Capsugel's lipid-based formulation expertise and manufacturing capability.
Under the collaboration,Quotient will utilise Capsugel's CFS Liquid Capsule Filling and Sealing technology at its Nottingham facility and will be able to access the formulation expertise in Capsugel's Development Centre in Strasbourg.
Quotient Clinical managing director Mark Egerton said the collaboration with Capsugel will help the customers address prevalent drug delivery challenges for poorly soluble compounds in an effective way.
"It will further empower our RapidFACT service by ensuring that selected drug products can be rapidly scaled-up and transitioned into downstream development-further reducing timelines to critical development milestones,"Egerton added.
Capsugel R&D senior vice president Keith Hutchison said,"Our expertise with poorly soluble drugs includes a proprietary predictive modeling technology based on an extensive database of lipid formulations that allows us to find the best formulas quickly."
